Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | EGFRt/19-28z/4-1BBL CAR T cells |
Trade Name | |
Synonyms | |
Drug Descriptions |
EGFRt/19-28z/4-1BBL CAR T cells are autologous T-cells engineered to express TNFSF9 (4-1BBL) and a chimeric antigen receptor (CAR) targeting CD19 linked to CD28 and CD3zeta signaling domains as well as a truncated EGFR, which may relieve immunosuppression and enhance cytotoxicity against CD19-expressing tumor cells (NCI Thesaurus). |
DrugClasses | CD19 Immune Cell Therapy 65 |
CAS Registry Number | NA |
NCIT ID | C133189 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
EGFRt/19-28z/4-1BBL CAR T cells | EGFRt/19-28z/4-1BBL CAR T cells | 0 | 1 |